Patents by Inventor Stuart Walsh
Stuart Walsh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250361282Abstract: The present invention relates to an antibody or a fragment thereof comprising at least one heterologous amino acid sequence incorporated within at least one CDR region of said antibody or fragment thereof, wherein said at least one heterologous amino acid sequence comprises an N-terminal linker sequence (Nils), an Atrial Natriuretic Peptide (ANP) and a C-terminal linker sequence (Ctls). Optionally, at least a portion of said at least one CDR region is replaced by said at least one heterologous amino acid sequence incorporated therein. The present invention further relates to such antibody or fragment thereof for use in a method for treatment, a composition comprising such antibody or fragment thereof, a nucleic acid or a mixture of nucleic acids encoding such antibody or fragment thereof, a host cell comprising such nucleic acid or such mixture of nucleic acids and to a process for producing such antibody or fragment thereof.Type: ApplicationFiled: May 12, 2025Publication date: November 27, 2025Applicant: Bayer AktiengesellschaftInventors: Anke MAYER-BARTSCHMID, Damian BROCKSCHNIEDER, Marcel GEERTZ, Simone GREVEN, Lucas Hudson HOFMEISTER, Hannah JÖRISSEN, Christoph MAHLERT, Tobias MARQUARDT, IIka MATHAR, Thomas MONDRITZKI, Claudia NOACK, Jan TEBBE, Stuart WALSH, Ernst WEBER, Andreas WILMEN, Frank WUNDER
-
Publication number: 20250236654Abstract: The present invention relates to an antibody or a fragment thereof comprising at least one heterologous amino acid sequence incorporated within at least one CDR region of said antibody or fragment thereof, wherein said at least one heterologous amino acid sequence comprises an N-terminal linker sequence (Ntls), a C-Type Natriuretic Peptide (CNP) and a C-terminal linker sequence (Ctls). Optionally, at least a portion of said at least one CDR region is replaced by said at least one heterologous amino acid sequence incorporated therein. The present invention further relates to such antibody or fragment thereof for use in a method for treatment, a composition comprising such antibody or fragment thereof, a nucleic acid or a mixture of nucleic acids encoding such antibody or fragment thereof, a host cell comprising such nucleic acid or such mixture of nucleic acids and to a process for producing such antibody or fragment thereof.Type: ApplicationFiled: December 5, 2024Publication date: July 24, 2025Applicant: Bayer AktiengesellschaftInventors: Damian BROCKSCHNIEDER, Lucas Hudson HOFMEISTER, Claudia NOACK, Jan TEBBE, Stuart WALSH, Andreas WILMEN, Frank WUNDER
-
Patent number: 12331094Abstract: The present invention relates to an antibody or a fragment thereof comprising at least one heterologous amino acid sequence incorporated within at least one CDR region of said antibody or fragment thereof, wherein said at least one heterologous amino acid sequence comprises an N-terminal linker sequence (Nils), an Atrial Natriuretic Peptide (ANP) and a C-terminal linker sequence (Ctls). Optionally, at least a portion of said at least one CDR region is replaced by said at least one heterologous amino acid sequence incorporated therein. The present invention further relates to such antibody or fragment thereof for use in a method for treatment, a composition comprising such antibody or fragment thereof, a nucleic acid or a mixture of nucleic acids encoding such antibody or fragment thereof, a host cell comprising such nucleic acid or such mixture of nucleic acids and to a process for producing such antibody or fragment thereof.Type: GrantFiled: April 10, 2019Date of Patent: June 17, 2025Assignee: Bayer AktiengesellschaftInventors: Anke Mayer-Bartschmid, Damian Brockschnieder, Marcel Geertz, Simone Greven, Lucas Hudson Hofmeister, Hannah Jörissen, Christoph Mahlert, Tobias Marquardt, Ilka Mathar, Thomas Mondritzki, Claudia Noack, Jan Tebbe, Stuart Walsh, Ernst Weber, Andreas Wilmen, Frank Wunder
-
Publication number: 20210139555Abstract: The present invention relates to an antibody or a fragment thereof comprising at least one heterologous amino acid sequence incorporated within at least one CDR region of said antibody or fragment thereof, wherein said at least one heterologous amino acid sequence comprises an N-terminal linker sequence (Nils), an Atrial Natriuretic Peptide (ANP) and a C-terminal linker sequence (Ctls). Optionally, at least a portion of said at least one CDR region is replaced by said at least one heterologous amino acid sequence incorporated therein. The present invention further relates to such antibody or fragment thereof for use in a method for treatment, a composition comprising such antibody or fragment thereof, a nucleic acid or a mixture of nucleic acids encoding such antibody or fragment thereof, a host cell comprising such nucleic acid or such mixture of nucleic acids and to a process for producing such antibody or fragment thereof.Type: ApplicationFiled: April 10, 2019Publication date: May 13, 2021Applicant: Bayer AktiengesellschaftInventors: Anke MAYER-BARTSCHMID, Damian BROCKSCHNIEDER, Marcel GEERTZ, Simone GREVEN, Lucas Hudson HOFMEISTER, Hannah JÖRISSEN, Christoph MAHLERT, Tobias MARQUARDT, Ilka MATHAR, Thomas MONDRITZKI, Claudia NOACK, Jan TEBBE, Stuart WALSH, Ernst WEBER, Andreas WILMEN, Frank WUNDER
-
Publication number: 20210079056Abstract: The present invention relates to an antibody or a fragment thereof comprising at least one heterologous amino acid sequence incorporated within at least one CDR region of said antibody or fragment thereof, wherein said at least one heterologous amino acid sequence comprises an N-terminal linker sequence (Ntls), a C-Type Natriuretic Peptide (CNP) and a C-terminal linker sequence (Ctls). Optionally, at least a portion of said at least one CDR region is replaced by said at least one heterologous amino acid sequence incorporated therein. The present invention further relates to such antibody or fragment thereof for use in a method for treatment, a composition comprising such antibody or fragment thereof, a nucleic acid or a mixture of nucleic acids encoding such antibody or fragment thereof, a host cell comprising such nucleic acid or such mixture of nucleic acids and to a process for producing such antibody or fragment thereof.Type: ApplicationFiled: April 10, 2019Publication date: March 18, 2021Applicant: Bayer AktiengesellschaftInventors: Damian BROCKSCHNIEDER, Lucas Hudson HOFMEISTER, Claudia NOACK, Jan TEBBE, Stuart WALSH, Andreas WILMEN, Frank WUNDER
-
Publication number: 20040225564Abstract: Systems and methods for providing customizable music, advertisements and/or other content to a remote business or retail location. One or more player devices are configured to selectively broadcast customizable music, advertisements and/or other content at remote business locations. A system, architecture or interface is used to deliver the customizable music and/or advertisements to the remote retail locations for the broadcast. The player devices are each located in a retail location and may be grouped according to retail chains or any other common characteristic between the retail locations, the content broadcast, etc. Optionally, a chain manager oversees or manages the content that is broadcast at a particular group of player devices. The content may be customized to particular retail chains/groupings, to neighborhood environments, business types, etc.Type: ApplicationFiled: February 3, 2004Publication date: November 11, 2004Inventors: Stuart Walsh, Kent Kvarfordt, Linwood Register, Robert Powell